Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ipsen's New CEO Targets At Least One New Drug Annually 'Forever'

Executive Summary

The French pharma under its American CEO plans to transform itself through R&D and M&A, and promises to launch at least one new drug or new valuable indication every year - "forever".

You may also be interested in...



Europe's Biopharma Sector Could Be In For Bumper Year

The Belgian biotechs Ablynx and Galapagos are among the companies that are likely to have a very interesting 2018, according to analysts, and the sector in Europe as a whole is set for consolidation and more drugs getting to market, helped by a supportive regulatory landscape.

Ipsen Shores Up Cash-Generating Primary Care Business With Sanofi CHC Buy

Ipsen has picked up five of Sanofi's consumer healthcare products in certain European markets to enable the larger company's deal with Boehringer Ingelheim to proceed. Despite moves by Ipsen to bolster its cash-generating primary care business, some analysts still believe a sale could make good business sense.

From Onivyde To OTx: Ipsen Fortifies Oncology with Primary Care Dealmaking

Ipsen's cash-generating primary care business is supporting a flurry of activity in its larger specialty care franchise. The French pharma has just signed a new deal with Italian company Akkadeas Pharma to give it a boost in primary care.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel